In a phase II trial, monalizumab in combination with durvalumab versus anti-PD-L1 alone showed improvements in ORR and PFS in stage III unresectable NSCLC in patients who did not progress to concomitant chemo- or radiotherapy [183]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.